Is serum matrix metalloproteinase 9 a useful biomarker in detection of colorectal cancer? Considering pre-analytical interference that may influence diagnostic accuracy.
Jung K
Purpose
Conclusion
Studies (1)
Purpose
The purpose of this study was to determine the effects of anticoagulant and collection tube type on MMP-9 levels in plasma and serum. All specimens were frozen prior to analysis.
Summary of Findings
Serum specimen collected with or without clot activator had more MMP-9 than plasma specimens, regardless of the anticoagulant. The higher levels of MMP-9 in serum were attributed to release of MMP-9 during coagulation. When collected without clot activator, serum had only 29% as much MMP-9 as was found when specimens were collected with clot activator. Compared to serum specimens collected with clot activator, significantly less MMP-9 was measured when plasma was collected with EDTA (17%), lithium heparin (7.5%), or sodium citrate (6%). The authors conclude that only plasma specimens are suitable for quantification of MMP-9.
Biospecimens
FluidPlasmaFluidSerumFluidBloodPreservation Types
FrozenDiagnoses
NormalPlatforms
ProteinClinical chemistry/auto analyzerPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Biospecimen Acquisition Anticoagulant EDTALithium heparinNoneSodium citrateBiospecimen Aliquots and Components Blood and blood products PlasmaSerum